Progyny, INC

Progyny, Inc. announced amendments to its Certificate of Incorporation and Bylaws, effective May 21, 2026, eliminating certain supermajority voting requirements.

Progyny's Board of Directors has authorized a new share repurchase program allowing for the buyback of up to $200 million of its common stock.

Progyny announced record first quarter 2026 revenue of $328.5 million, driven by robust demand for its women's health and family building solutions and a 12.2% increase excluding a former large client.

Progyny, Inc. announces settlement of a derivative action, implementing new corporate governance reforms to cap non-employee director compensation.

Progyny, a leader in women's health and family building solutions, announced record full-year 2025 financial results and provided optimistic guidance for 2026.

Progyny, Inc. announced updated financial expectations for Q4 and full year 2025, anticipating results slightly above previous guidance.

Progyny, Inc. announced its Q2 2026 results, showcasing a 5% increase in revenue driven by its fertility and pharmacy benefits solutions, alongside a notable improvement in gross margin.

Progyny, Inc. reports a significant 61% increase in net income for Q1 2026, driven by client expansion and improved gross margin, despite a modest 1% revenue growth.

Progyny, Inc. reported strong third-quarter 2025 financial results with a 9% revenue increase and a 33% rise in net income, driven by growth in fertility benefits and Progyny Rx solutions.

Progyny, Inc. reports strong revenue growth and improved gross margins in Q2 2025, driven by increased client adoption and utilization of its fertility and pharmacy benefits solutions.

Progyny's Q1 2025 results show a 17% increase in revenue, driven by growth in both fertility benefits and pharmacy solutions, alongside an expanding client base.

Progyny's Q3 2024 results show a slight revenue increase but a decrease in net income compared to the same period last year, alongside a significant share repurchase program.

Progyny, Inc. announced a 10% revenue increase to $1.29 billion in 2025, driven by expanded fertility and family building solutions and a growing client base, alongside a new $200 million share repurchase program.

Progyny, Inc.'s 2024 10-K filing reveals a year of revenue growth, strategic acquisitions, and ongoing efforts to manage risks and expand its market presence despite the loss of a major client.

Progyny, Inc.'s 10-K filing details the company's capital structure, voting rights, and anti-takeover provisions as of December 31, 2023.

Geoffrey Clapp, Chief Product Officer of Progyny, Inc., reported a transaction in 819 shares of common stock on September 17, 2026.

Kevin K Gordon, a Director of Progyny, Inc., sold 11,500 shares of common stock on September 10, 2026 for $27.12 per share.

Kevin K Gordon, a Director of Progyny, Inc., sold 11,500 shares of common stock on September 10, 2026 for $27.94 per share.

Peter Anevski, CHIEF EXECUTIVE OFFICER and a Director of Progyny, Inc., reported a transaction in 5,361 shares of common stock on September 3, 2026.

Allison Swartz, EVP, GC of Progyny, Inc., reported multiple transactions in common stock on September 3, 2026.

Mark S. Livingston, CHIEF FINANCIAL OFFICER of Progyny, Inc., reported a transaction in 479 shares of common stock on September 4, 2026.

Progyny, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 21, 2026, to be held virtually, and has proposed amendments to its Certificate of Incorporation to eliminate certain supermajority voting requirements.

A proxy statement has been filed.

Progyny, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on May 22, 2025, to vote on director elections, ratification of the independent auditor, and executive compensation.

A preliminary proxy statement has been filed, indicating upcoming corporate actions requiring shareholder votes.

Progyny, Inc. has set its 2024 Annual Meeting of Stockholders for May 23, 2024, to address director elections, auditor ratification, executive compensation, and other business.

Progyny, Inc. files an amendment to its Schedule 13G, reporting zero shares beneficially owned by Kleiner Perkins entities as of March 31, 2025.

Vanguard Portfolio Management has reported a beneficial ownership of 6.54% of Progyny Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Progyny Inc. common stock following an internal realignment that disaggregated reporting responsibilities.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 7.6% in Progyny Inc.'s common stock as of September 30, 2025.

FMR LLC and Abigail P. Johnson have disclosed a beneficial ownership of 5.5% of Progyny Inc.'s common stock as of June 30, 2025.

The Vanguard Group has reported a significant 11.51% beneficial ownership stake in Progyny Inc., holding 9,870,634 common shares as a passive investment.